When do you consider HER2-targeting antibody drug conjugates in the first line setting for metastatic HER2 positive, ER negative breast cancer?  

Given strong TDXd efficacy in these patients is there a role to use it earlier than 2nd line?

How does prior Her2-directed and/or taxane therapy affect your decision?



Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Community Practice

Answer from: Medical Oncologist at Academic Institution
Comments
Medical Oncologist at UPMC Cancer Center
Thank you for the excellent summary. Such appropri...
Sign in or Register to read more

Answer from: Medical Oncologist at Community Practice

Answer from: Medical Oncologist at Community Practice